"Collateral damage" Antibiotics and the risk of Clostridium difficile infection

Orthopedics

Volumn 28, Issue 3, 2005, Pages 275-279

  Yam, Felix K ^a   Smith, Kelly M ^a,b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b Dept of Pharmacy ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFALEXIN; CEPHALOSPORIN; CLINDAMYCIN; GATIFLOXACIN; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE; DIARRHEA; DISEASE SEVERITY; DRUG FORMULARY; DRUG UTILIZATION; DRUG WITHDRAWAL; ENVIRONMENTAL EXPOSURE; FEEDING APPARATUS; GASTROINTESTINAL SURGERY; HUMAN; INCIDENCE; MEDICAL DECISION MAKING; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; ORTHOPEDIC SURGERY; POSTOPERATIVE INFECTION; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SURGICAL PATIENT;

EID: 15844430997     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/0147-7447-20050301-12     Document Type: Article

References (25)

1. Holtom P, Patzakis, M. Open fractures and postoperative orthopedic infections. Current Treatment Options in Infectious Diseases. 2000; 2:208-213.
2. Gorbach SL. Antibiotics and Clostridium difficile. N Engl J Med. 1999; 341:1690-1691.
3. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002; 34:346-353.
4. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002; 346:334-339.
5. Eggertson L. C. difficile: by the numbers. CMAJ. 2004; 171:1331-1332.
6. Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med. 1999; 341:1645-1651.
7. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004; 171:33-38.
8. Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol. 2001; 15:511-521.
9. Sharma P, Bomireddy R, Phillips S. Clostridium difficile-associated diarrhoea after internal fixation of intertrochanteric femoral fractures. Eur J Clin Microbiol Infect Dis. 2003; 22:615-618.
10. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ. 2004; 171:51-58.
11. Kreisel D, Savel TG, Silver AL, Cunningham JD. Surgical antibiotic prophylaxis and Clostridium difficile toxin positivity. Arch Surg. 1995; 130:989-993.
12. Mader JT, Wang J, Calhoun JH. Antibiotic therapy for musculoskeletal infections. Instr Course Lect. 2002; 51:539-551.
13. Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med. 1998; 128:989-995.
14. McEniry DW, Gorbach SL. Cephalosporins in surgery. Prophylaxis and therapy. Drugs. 1987; 34 (Suppl 2):216-239.
15. Dancer SJ. The problem with cephalosporins. J Antimicrob Chemother. 2001; 48:463-478.
16. Privitera G, Scarpellini P, Ortisi G, Nicastro G, Nicolin R, de Lalla F. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother. 1991; 35:208-210.
17. McCusker ME, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis. 2003; 9:730-733.
18. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis. 2004; 38:640-645.
19. Wilcox MH, Fawley W, Freeman J, Brayson J. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother. 2000; 46:551-556.
20. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis. 1996; 23:1020-1025.
21. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995; 16:459-477.
22. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 1997; 92:739-750.
23. Pelaez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother. 2002; 46:1647-1650.
24. Shin M Yong D, Kim MS, et al. Sudden increase of vancomycin-resistant enterococcal infections in a Korean tertiary care hospital: possible consequences of increased use of oral vancomycin. J Infect Chemother. 2003; 9:62-67; discussion 104-105.
25. Morris JG Jr, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med. 1995; 123:250-259.